Volume 19 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(5): 756-759
SU Kui-wei, LI Xiao, CHENG Gang. The relationship between the expression of HYAL1 and the progression and prognosis of head and neck squamous cell carcinoma[J]. Chinese Journal of General Practice, 2021, 19(5): 756-759. doi: 10.16766/j.cnki.issn.1674-4152.001909
Citation: SU Kui-wei, LI Xiao, CHENG Gang. The relationship between the expression of HYAL1 and the progression and prognosis of head and neck squamous cell carcinoma[J]. Chinese Journal of General Practice, 2021, 19(5): 756-759. doi: 10.16766/j.cnki.issn.1674-4152.001909
shu

The relationship between the expression of HYAL1 and the progression and prognosis of head and neck squamous cell carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.001909
  • 1.

    Graduate School of Bengbu Medical College, Bengbu, Anhui 233030, China

Funds:

 KJ2016A480

  • Received Date: 2020-09-21
    Available Online: 2022-02-16
    Abstract
  •   Objective  This article aims to study the expression level of hyaluronidase 1 (HYAL1) in head and neck squamous cell carcinoma (HNSCC) and its relationship with the survival of HNSCC patients.  Methods  The data of HNSCC patients who underwent radical resection in Zhejiang Provincial People's Hospital from 2008 to 2015 were collected to construct tissue chips, and the expression of HYAL1 in tumor specimens and nearby tissues from 258 patients was detected by immunohistochemistry.  Results  The expression of HYAL1 in HNSCC tissues was significantly lower than that of normal adjacent tissues (P < 0.001). The low expression of HYAL1 was significantly correlated with tumor size (P=0.011), lymph node metastasis (P=0.025) and TNMs staging system (P=0.038). In addition, compared with high HYAL1 expression, low HYAL1 expression was significantly associated with short survival time (P=0.007). The median overall survival of patients with low HYAL1 expression is 36 months, while the median overall survival of patients with high HYAL1 expression has not yet reached (more than 74 months). It is worth noting that in our limited cases, this study did not find any difference in age, gender, lesion site, HPV infection, smoking, drinking, and histological staging between the patients with high low expression of HYAL1.  Conclusion  The low expression of HYAL1 is related to the poor prognosis of these HNSCC patients. HYAL1 may be a clinically valuable prognostic indicator and a potential target for HNSCC treatment.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
    [2]
    LIU S, WOODY N, WEI W, et al. Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration study[J]. Head Neck, 2021, 43(1): 60-69. doi: 10.1002/hed.26454
    [3]
    GOU Y, SHI M, YANG A, et al. Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial[J]. Head Neck, 2015, 37(8): 1081-1087. doi: 10.1002/hed.23707
    [4]
    CHANG Y, CHU L, LIU Y, et al. Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer[J]. Cancers (Basel), 2020, 12(8): 2273-2290. doi: 10.3390/cancers12082273
    [5]
    WICKER C, TAKIAR V, SUGANYA R, et al. Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients[J]. Oral Oncol, 2020, 111: 104949. doi: 10.1016/j.oraloncology.2020.104949
    [6]
    张宁, 兰雪玲. 铁蛋白在头颈癌颈部淋巴结转移的预测作用[J]. 实用肿瘤学杂志, 2019, 33(5): 442-446. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL201905014.htm
    [7]
    SPINELLI F, VITALE D, SEVIC I, et al. Hyaluronan in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1245: 67-83. doi: 10.1007/978-3-030-40146-7_3
    [8]
    DUAN H, DONOVAN M, HERNANDEZ F, et al. Hyaluronic-acid-presenting self-assembled nanoparticles transform a hyaluronidase HYAL1 substrate into an efficient and selective inhibitor[J]. Angew Chem Int Ed Engl, 2020, 59(32): 13591-13596. doi: 10.1002/anie.202005212
    [9]
    LENG D, HUANG X, YI J, et al. HYAL1 is downregulated in idiopathic pulmonary fibrosis and inhibits HFL-1 fibroblast proliferation when upregulated[J]. Biomed Res Int, 2020, 2020: 3659451. http://www.researchgate.net/publication/339866044_HYAL1_Is_Downregulated_in_Idiopathic_Pulmonary_Fibrosis_and_Inhibits_HFL-1_Fibroblast_Proliferation_When_Upregulated
    [10]
    WITZEL I, MARX A, MULLER V, et al. Role of HYAL1 expression in primary breast cancer in the formation of brain metastases[J]. Breast Cancer Res Treat, 2017, 162(3): 427-438. doi: 10.1007/s10549-017-4135-6
    [11]
    JIN Z, ZHANG G, LIU Y, et al. The suppressive role of HYAL1 and HYAL2 in the metastasis of colorectal cancer[J]. J Gastroenterol Hepatol, 2019, 34(10): 1766-1776. doi: 10.1111/jgh.14660
    [12]
    李志强, 姜书传, 马玲, 等. 膀胱移行癌中HYAL-1, CD44v6及MVD的临床意义[J]. 现代泌尿外科杂志, 2011, 16(5): 439-442. doi: 10.3969/j.issn.1009-8291.2011.05.018
    [13]
    FRANZMANN E, SCHROEDER G, GOODWIN W, et al. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors[J]. Int J Cancer, 2003, 106(3): 438-445. doi: 10.1002/ijc.11252
    [14]
    KAROUSOU E, MISRA S, GHATAK S, et al. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer[J]. Matrix Biol, 2017, 59: 3-22. doi: 10.1016/j.matbio.2016.10.001
    [15]
    AGARWAL G, KRISHNAN K V, PRASAD S, et al. Biosynthesis of Hyaluronic acid polymer: Dissecting the role of sub structural elements of hyaluronan synthase[J]. Sci Rep, 2019, 9(1): 12510. doi: 10.1038/s41598-019-48878-8
    [16]
    CHANMEE T, ONTONG P, ITANO N. Hyaluronan: A modulator of the tumor microenvironment[J]. Cancer Lett, 2016, 375(1): 20-30. doi: 10.1016/j.canlet.2016.02.031
    [17]
    SUN S, WON H, HONG S, et al. Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers[J]. Korean J Intern Med, 2020, 35(2): 408-420. doi: 10.3904/kjim.2018.203
    [18]
    FROST G, MOHAPATRA G, WONG T, et al. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA[J]. Oncogene, 2000, 19(7): 870-877. doi: 10.1038/sj.onc.1203317
    [19]
    POSEY J, SOLOWAY M, EKICI S, et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer[J]. Cancer Res, 2003, 63(10): 2638-2644. http://cancerres.aacrjournals.org/cgi/reprint/63/10/2638
    [20]
    CHENG X, WANG S, YANG H, et al. Negative regulation between the expression levels of receptor for hyaluronic acid-mediated motility and hyaluronan leads to cell migration in pancreatic cancer[J]. Oncol Lett, 2020, 20(5): 199-210.
    [21]
    MCATEE C, BOOTH C, ELOWSKY C, et al. Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling[J]. Matrix Biol, 2019, 78: 165-179. http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S0945053X1730464X&originContentFamily=serial&_origin=article&_ts=1526066327&md5=ba2d63a99b6b6460621fed0fcd6bb3c7
    [22]
    NYKOPP T, PASONEN-SEPPANEN S, TAMMI M, et al. Decreased hyaluronidase 1 expression is associated with early disease recurrence in human endometrial cancer[J]. Gynecol Oncol, 2015, 137(1): 152-160. doi: 10.1016/j.ygyno.2015.01.525
    [23]
    NAN H, YENER M, BUYRU N, et al. The investigation of hyaluronic acid and hyaluronidase-1 levels as tumour marker in larynx cancer[J]. Clin Otolaryngol, 2019, 44(6): 914-918. doi: 10.1111/coa.13390
    [24]
    HUANG Q, BELZ G. Parallel worlds of the adaptive and innate immune cell networks[J]. Curr Opin Immunol, 2019, 58: 53-59. doi: 10.1016/j.coi.2019.04.008
    [25]
    HAMADA M, YURA Y. Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer[J]. Int J Mol Sci, 2020, 21(19): 7073-7094. doi: 10.3390/ijms21197073
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (293) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return